Newcastle pharmacy experts work with Italian biotech lab to provide access to sight-saving treatment across England
June 24, 2022 – A life-changing treatment to reverse injury-related sight loss is now available to patients at specialist centres across England, thanks to a partnership between Newcastle Hospitals and Italian medicines manufacturer, Holostem.
The specialist advanced therapy, known as Holoclar, uses stem cells to treat sight loss due to physical or chemical burns to the eye. The treatment is made by taking healthy cells from the patient’s uninjured eye before sending them to Italy where they are used to cultivate a new corneal epithelium – the clear ‘barrier’ that protects the eye. The product must be transplanted onto the damaged eye within 36 hours of release.
This short shelf life makes timing critical and legislative constraints were making it difficult to import Holoclar for use at the four NHS sites approved to carry out the treatment.
Adam Walker, specialist quality assurance pharmacist at Newcastle Hospitals, explains how his team worked to unlock access for the wider NHS: “Over a number of months, quality assurance specialists from our pharmacy directorate worked extensively with Holostem, providing advice, guidance and support to overcome the import challenge and develop appropriate regulatory authorisations. Our work addressed the previous supply constraints, making the treatment quickly and easily available for NHS use, so specialist centres can now restore the sight of the patients who receive it. Using the same authorisations, our team is now in a position to assist other manufacturers to offer innovative products within the NHS.”
Irving Donandon from Holostem said: “Holoclar is available to patients in a number of other European countries and we wanted NHS patients in the UK to benefit too. This new distribution model is a fantastic collaboration between NHS pharmacists and private industry and has been fundamental to overcome the access constraints we experienced. With a joint focus on improving patient’s lives, our partnership proves how different sectors can work together to make the best possible treatments available to people.”
The partnership between the Newcastle Hospitals and Holostem was facilitated by the Northern Alliance Advanced Therapies Treatment Centre, which works to support the use of advanced therapies and ensure access for NHS patients.
- Newcastle pharmacy experts work with Italian biotech lab to provide access to sight-saving treatment across England
- Holostem Terapie Avanzate begins its transition to a Foundation
- Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
- Gene therapy for butterfly children: 5-year follow-up published in the New England Journal of Medicine
- Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa